J&J says CareFirst distorts the law in US antitrust case over Stelara
MLex Summary: Johnson & Johnson and Janssen Biotech filed a reply in support of judgment against CareFirst’s US antitrust case over Stelara, arguing that the opposition distorts the relevant law and...To view the full article, register now.
Already a subscriber? Click here to view full article